Silence Therapeutics plc
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
11. Capital commitments and contingent liabilities
There wereno capital commitments at June 30, 2026 or December 31, 2025.
- Related party transactions
None.
- Subsequent events
As previously reported, the Company and its former chief executive officer entered into a separation agreement in July 2026. The agreement resulted in a modification to the terms of the former executive’s unvested stock options in the event of a “change in control” as such term is defined in the Company’s equity incentive plan to be through December 14, 2026. The related value of this modification would be $1.4 million based on the fair value of the awards at the modification date and compensation will be recognized only when it is probable that the awards will vest. At the modification date, $0.9 million of share-based compensation expense will be credited for prior recognized expense.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.